bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX.

Company Data

Name bioAffinity Technologies, Inc. - Warrant

Company bioAffinity Technologies, Inc.

Symbol BIAFW

Website http://www.bioaffinitytech.com

Primary Exchange

NASDAQ

ISIN US09076W1172

Asset Class Share

Sector Healthcare

Industry Medical - Diagnostics & Research

CEO Maria Zannes

Country United States of America

Currency USD

Employees 0,1 T

Address 3300 Nacogdoches Road, San Antonio

Ticker Symbols

Name	Symbol
NASDAQ	BIAFW

More Shares

Investors who hold bioAffinity Technologies, Inc. - Warrant also have the following shares in their portfolio:

DANONE 16/26 REGS Bond

Hartford Schroders US Small Cap Opportunities Fund Class A Fund

The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.

Imprint Data Protection Blog Community Feedback Changelog